



## Clinical trial results:

**An open, single group, multi-centric, post marketing surveillance (PMS) to monitor the reactogenicity and safety of oral live attenuated human rotavirus (HRV) vaccine, Rotarix™ when administered according to the Prescribing Information (PI) to Indian infants**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2017-000451-14 |
| Trial protocol           | Outside EU/EEA |
| Global end of trial date | 23 April 2010  |

### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 20 December 2017 |
| First version publication date | 20 December 2017 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 112896 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT00938327 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | GlaxoSmithKline Biologicals   |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium,   |
| Public contact               | Clinical Trials Call Center, GlaxoSmithKline Biologicals, +((44)2089 904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | Clinical Trials Call Center, GlaxoSmithKline Biologicals, +((44)2089 904466, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

|  |     |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No  |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

---

**Results analysis stage**

---

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 23 April 2010    |
| Is this the analysis of the primary completion data? | Yes              |
| Primary completion date                              | 20 February 2010 |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 23 April 2010    |
| Was the trial ended prematurely?                     | No               |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To assess the reactogenicity of Rotarix in terms of occurrence of at least one Grade "2" or Grade "3" fever, vomiting or diarrhoea within the 8-day (Day 0-Day 7) follow-up period after any Rotarix vaccination

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes following the administration of vaccine, with appropriate medical treatment readily available in case of a rare anaphylactic reaction

Background therapy: -

Evidence for comparator: -

|   |                |
|---|----------------|
| Actual start date of recruitment                          | 03 August 2009 |
| Long term follow-up planned                               | No             |
| Independent data monitoring committee (IDMC) involvement? | No             |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |            |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | India: 332 |
| Worldwide total number of subjects   | 332        |
| EEA total number of subjects         | 0          |

Notes:

---

**Subjects enrolled per age group**

---

|   |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 332 |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 0   |
| From 65 to 84 years                       | 0   |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

|                              |     |
|------------------------------|-----|
| Number of subjects started   | 332 |
| Number of subjects completed | 332 |

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Not applicable                 |
| Blinding used                | Not blinded                    |

### Arms

|           |               |
|-----------|---------------|
| Arm title | Rotarix Group |
|-----------|---------------|

Arm description:

Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

|  |   |
|--|---|
| Arm type                               | Experimental                                      |
| Investigational medicinal product name | Rotarix™  |
| Investigational medicinal product code |   |
| Other name                             | GSK Biologicals' oral live attenuated HRV vaccine |
| Pharmaceutical forms                   | Powder and solvent for oral suspension            |
| Routes of administration               | Oral use  |

Dosage and administration details:

Two doses of Rotarix administered orally. First dose administered from the age of 6 weeks. Second dose administered at least 4 weeks after Dose 1. Vaccination course completed by 24 weeks of age

| Number of subjects in period 1         | Rotarix Group |
|--|---------------|
| Started                                | 332           |
| Completed                              | 272           |
| Not completed                          | 60            |
| Consent withdrawn by subject           | 4             |
| 2nd dose received outside of the study | 7             |
| Adverse event, non-fatal               | 2             |
| Vaccine not received as out of stock   | 9             |
| Lost to follow-up                      | 37            |
| Protocol deviation                     | 1             |



## Baseline characteristics

### Reporting groups

|                       |               |
|-----------------------|---------------|
| Reporting group title | Rotarix Group |
|-----------------------|---------------|

Reporting group description:

Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

| Reporting group values  | Rotarix Group  | Total |  |
|---|----------------|-------|--|
| Number of subjects  | 332            | 332   |  |
| Age categorical<br>Units: Subjects                                      |                |       |  |
| Age continuous<br>Units: weeks<br>arithmetic mean<br>standard deviation | 10.4<br>± 4.27 | -     |  |
| Gender categorical<br>Units: Subjects                                   |                |       |  |
| Female  | 155            | 155   |  |
| Male  | 177            | 177   |  |

## End points

### End points reporting groups

|  |               |
|--|---------------|
| Reporting group title  | Rotarix Group |
| Reporting group description:<br>Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses. |               |

### Primary: Number of subjects reporting Grade 2 or 3 symptoms (fever, vomiting or diarrhoea)

|                 |  |
|-----------------|--|
| End point title | Number of subjects reporting Grade 2 or 3 symptoms (fever, vomiting or diarrhoea) <sup>[1]</sup> |
|-----------------|--|

End point description:

Grade 2 fever was defined as axillary temperature above 38.0 degrees Celsius (°C) and below or equal to 39.0°C. Grade 3 fever was defined as axillary temperature above 39.0°C. Grade 2 vomiting was defined as 2 episodes of vomiting per day. Grade 3 vomiting was defined as at least 3 episodes of vomiting per day. Grade 2 diarrhoea was defined as 4-5 looser than normal stools per day. Grade 3 diarrhoea was defined as at least 6 looser than normal stools per day.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 8-day (Day 0 – Day 7) follow-up period after each vaccination.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Rotarix Group   |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 332             |  |  |  |
| Units: subjects             |                 |  |  |  |
| subjects                    | 42              |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting solicited general symptoms

|                 |   |
|-----------------|---|
| End point title | Number of subjects reporting solicited general symptoms |
|-----------------|---|

End point description:

Cough: Cough/runny nose of any intensity Diarrhoea: Passage of three or more looser than normal stools within a day Irritability: Cried more than usual Loss of appetite: Ate less than usual Temperature: Axillary temperature greater than or equal to 37.5°C Vomiting: One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 8-day (Day 0 – Day 7) follow-up period after each vaccination

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Rotarix Group   |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 332             |  |  |  |
| Units: subjects             |                 |  |  |  |
| Cough                       | 43              |  |  |  |
| Diarrhoea                   | 14              |  |  |  |
| Irritability                | 81              |  |  |  |
| Loss of appetite            | 46              |  |  |  |
| Temperature (axillary)      | 24              |  |  |  |
| Vomiting                    | 67              |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting unsolicited adverse events (AEs)

|                 |   |
|-----------------|---|
| End point title | Number of subjects reporting unsolicited adverse events (AEs) |
|-----------------|---|

End point description:

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 31-day (Day 0 – Day 30) follow-up period after each vaccination

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Rotarix Group   |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 332             |  |  |  |
| Units: subjects             |                 |  |  |  |
| subjects                    | 23              |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting serious adverse events (SAEs)

|                 |  |
|-----------------|--|
| End point title | Number of subjects reporting serious adverse events (SAEs) |
|-----------------|--|

End point description:

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

|   |           |
|---|-----------|
| End point type  | Secondary |
| End point timeframe:                                  |           |
| Throughout the study period (from Day 0 up to Day 30) |           |

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Rotarix Group   |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 332             |  |  |  |
| Units: subjects             |                 |  |  |  |
| subjects                    | 0               |  |  |  |

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious adverse events: throughout the study period (Day 0-Day 30). Other adverse events: during the 8-day (Day 0-Day 7) follow-up period after each vaccination.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                    |        |
|--------------------|--------|
| Dictionary name    | MedDRA |
| Dictionary version | 13.0   |

### Reporting groups

|                       |               |
|-----------------------|---------------|
| Reporting group title | Rotarix Group |
|-----------------------|---------------|

Reporting group description:

Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

| Serious adverse events                            | Rotarix Group   |  |  |
|---|-----------------|--|--|
| Total subjects affected by serious adverse events |                 |  |  |
| subjects affected / exposed                       | 0 / 332 (0.00%) |  |  |
| number of deaths (all causes)                     | 0               |  |  |
| number of deaths resulting from adverse events    | 0               |  |  |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events                            | Rotarix Group      |  |  |
|---|--------------------|--|--|
| Total subjects affected by non-serious adverse events |                    |  |  |
| subjects affected / exposed                           | 133 / 332 (40.06%) |  |  |
| Nervous system disorders                              |                    |  |  |
| Hypersomnia   |                    |  |  |
| subjects affected / exposed                           | 1 / 332 (0.30%)    |  |  |
| occurrences (all)                                     | 1                  |  |  |
| Lethargy  |                    |  |  |
| subjects affected / exposed                           | 1 / 332 (0.30%)    |  |  |
| occurrences (all)                                     | 1                  |  |  |
| General disorders and administration site conditions  |                    |  |  |
| Inflammation  |                    |  |  |

|   |  |  |  |
|---|--|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>  | <p>1 / 332 (0.30%)</p> <p>1</p> <p>25 / 332 (7.53%)</p> <p>28</p>  |  |  |
| <p>Eye disorders</p> <p>Lacrimation increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>   | <p>1 / 332 (0.30%)</p> <p>1</p>  |  |  |
| <p>Gastrointestinal disorders</p> <p>Abdominal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Flatulence</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Tongue discolouration</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 332 (0.30%)</p> <p>1</p> <p>3 / 332 (0.90%)</p> <p>3</p> <p>16 / 332 (4.82%)</p> <p>18</p> <p>1 / 332 (0.30%)</p> <p>1</p> <p>1 / 332 (0.30%)</p> <p>1</p> <p>67 / 332 (20.18%)</p> <p>83</p> |  |  |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rhinorrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>  | <p>45 / 332 (13.55%)</p> <p>55</p> <p>2 / 332 (0.60%)</p> <p>2</p>   |  |  |
| <p>Skin and subcutaneous tissue disorders</p>   |  |  |  |

|  |                         |  |  |
|--|-------------------------|--|--|
| Dermatitis atopic<br>subjects affected / exposed<br>occurrences (all)  | 2 / 332 (0.60%)<br>2    |  |  |
| Rash vesicular<br>subjects affected / exposed<br>occurrences (all)   | 1 / 332 (0.30%)<br>1    |  |  |
| Rash<br>subjects affected / exposed<br>occurrences (all)   | 1 / 332 (0.30%)<br>1    |  |  |
| Psychiatric disorders<br>Decreased activity<br>subjects affected / exposed<br>occurrences (all)              | 1 / 332 (0.30%)<br>1    |  |  |
| Irritability<br>subjects affected / exposed<br>occurrences (all)   | 81 / 332 (24.40%)<br>97 |  |  |
| Renal and urinary disorders<br>Pollakiuria<br>subjects affected / exposed<br>occurrences (all)               | 1 / 332 (0.30%)<br>1    |  |  |
| Infections and infestations<br>Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)           | 3 / 332 (0.90%)<br>3    |  |  |
| Otitis media acute<br>subjects affected / exposed<br>occurrences (all)                                       | 1 / 332 (0.30%)<br>1    |  |  |
| Metabolism and nutrition disorders<br>Decreased appetite<br>subjects affected / exposed<br>occurrences (all) | 46 / 332 (13.86%)<br>54 |  |  |

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported